CD274 and renal cell carcinoma: The IMmotion-151 phase III study of atezolizumab plus bevacizumab versus sunitinib in untreated metastatic RCC patients demonstrated an improvement in PFS with the combination ICI-based regimen in PD-L1-positive patients.